¼¼°èÀÇ ½º¸¶Æ® ÈíÀԱ⠽ÃÀå
Smart Inhalers
»óǰÄÚµå : 1795354
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 130 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,183,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,550,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½º¸¶Æ® ÈíÀԱ⠼¼°è ½ÃÀåÀº 2030³â±îÁö 1¾ï 9,220¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 9,900¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ½º¸¶Æ® ÈíÀԱ⠼¼°è ½ÃÀåÀº 2030³â¿¡´Â 1¾ï 9,220¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 11.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÈíÀÔ±â´Â CAGR 9.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 1,080¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ³×ºí¶óÀÌÀú ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 14.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2,600¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 11.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½º¸¶Æ® ÈíÀԱ⠽ÃÀåÀº 2024³â¿¡ 2,600¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ 2024³âºÎÅÍ 2030³â±îÁö CAGR 11.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 3,010¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 10.5%¿Í 10.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 8.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ½º¸¶Æ® ÈíÀԱ⠽ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

½º¸¶Æ® ÈíÀÔ±â´Â È£Èí Ä¡·áÀÇ ¿À·£ °úÁ¦¸¦ ¾î¶»°Ô ÇØ°áÇϰí Àִ°¡?

½º¸¶Æ® ÈíÀÔ±â´Â ±âÁ¸ÀÇ ÈíÀÔ ¸ÞÄ¿´ÏÁòÀ» µðÁöÅÐ ¿¬°á, ¼¾¼­, µ¥ÀÌÅÍ ºÐ¼®°ú °áÇÕÇÏ¿© õ½Ä, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD)°ú °°Àº ¸¸¼º È£Èí±âÁúȯÀÇ °ü¸®¸¦ Çõ½ÅÀûÀ¸·Î º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ ÀåÄ¡´Â ½Ç½Ã°£ »ç¿ë µ¥ÀÌÅ͸¦ ¼öÁýÇϰí, ÈíÀÔ ÆÐÅÏÀ» ÃøÁ¤Çϰí, ¼øÀÀµµ¸¦ ¸ð´ÏÅ͸µÇϰí, ºí·çÅõ½º Áö¿ø ¸ð¹ÙÀÏ ¾ÛÀ» ÅëÇØ ȯÀÚ ¹× ÀÇ·áÁø¿¡°Ô Á¤º¸¸¦ Àü¼ÛÇÕ´Ï´Ù. ½º¸¶Æ® ÈíÀÔ±â´Â ȯÀÚÀÇ Çൿ°ú ÀÓ»ó °á°ú »çÀÌÀÇ µ¥ÀÌÅÍ °ÝÂ÷¸¦ ÇØ¼ÒÇÏ¿© »çÀü ¿¹¹æÀû Áúº´ °ü¸®¿Í °³º°È­µÈ Ä¡·á ÃÖÀûÈ­¸¦ Áö¿øÇÕ´Ï´Ù.

±âÁ¸ ÈíÀÔ Ä¡·áÀÇ ÁÖ¿ä ÇѰè´Â ȯÀÚÀÇ ºñ¼øÀÀ¼º°ú À߸øµÈ ÈíÀÔ ±â¼ú·Î Ä¡·á È¿°ú¸¦ ÇöÀúÈ÷ ¶³¾î¶ß¸®´Â ¿äÀÎÀ̾ú½À´Ï´Ù. ½º¸¶Æ® ÈíÀÔ±â´Â º¹¿ëÀÇ Á¤È®¼º, ºóµµ, ŸÀ̹ÖÀ» ÃßÀûÇϰí, »ç¿ë ÇൿÀ» ¼öÁ¤Çϱâ À§ÇÑ ½Ãû°¢Àû ¾Ë¸²°ú ÄÚĪ Çǵå¹éÀ» Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÕ´Ï´Ù. ÀÌ µ¥ÀÌÅÍ´Â ÀÓ»óÀǰ¡ Áõ»ó Á¶ÀýÀ» Æò°¡Çϰí, ¾à¹° ¿ä¹ýÀ» ¹Ì¼¼ Á¶Á¤Çϰí, ÇÇÇÒ ¼ö ÀÖ´Â ÀÔ¿øÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ƯÈ÷ ¼Ò¾Æ, ³ëÀÎ, °Ç°­ ¹®ÇØ·ÂÀÌ ³·Àº ȯÀÚ¿¡°Ô ½º¸¶Æ® ÈíÀÔ±â´Â ½Ç½Ã°£ Áö¿ø°ú Ã¥ÀÓ°¨À» Á¦°øÇÏ¿© Áúº´À» ÅëÁ¦ÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

¾î¶² ±â¼ú°ú ±â´ÉÀÌ ½º¸¶Æ® ÈíÀÔ ÀåÄ¡ÀÇ Çõ½ÅÀ» ÁÖµµÇϰí Àִ°¡?

½º¸¶Æ® ÈíÀÔ±â´Â ½Ç½Ã°£ ¸ð´ÏÅ͸µ, µ¥ÀÌÅÍ ¼öÁý, ÀÇ»ç°áÁ¤ Áö¿øÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ÀÏ·ÃÀÇ ÅëÇÕ ±â¼úÀ» Ȱ¿ëÇÕ´Ï´Ù. ³»ÀåµÈ À¯·® ¼¾¼­¿Í °¡¼Óµµ°è°¡ ÈíÀÔ °­µµ, ½Ã°£, ºóµµ¸¦ °¨ÁöÇÏ°í ¸¶ÀÌÅ©·ÎÄÁÆ®·Ñ·¯°¡ ÀÛµ¿ À̺¥Æ®¸¦ ±â·ÏÇÕ´Ï´Ù. BLE(Bluetooth Low Energy) ¸ðµâÀº ÀÌ µ¥ÀÌÅ͸¦ ÄÄÆÐ´Ï¾ð ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼ÇÀ̳ª Ŭ¶ó¿ìµå ´ë½Ãº¸µå·Î Àü¼ÛÇÏ¿© ºÐ¼®Çϰųª ÀÇ·á Àü¹®°¡¿Í °øÀ¯ÇÒ ¼ö ÀÖ½À´Ï´Ù. À½Çâ ¼¾¼­¸¦ »ç¿ëÇÏ¿© È£ÈíÀ½À» Æò°¡ÇÏ°í ±âħ, õ¸íÀ½, ÀûÀýÇÑ Èí±â¸¦ ±¸ºÐÇÏ´Â ¸ðµ¨µµ ÀÖ½À´Ï´Ù.

¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼ÇÀº »ç¿ëÀÚ Âü¿©¿¡ ÀÖ¾î ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾ÖÇø®ÄÉÀ̼ÇÀº Ãß¼¼¸¦ ½Ã°¢È­Çϰí, º¹¾à ¾Ë¸²À» Àü¼ÛÇϰí, »ç¿ëÀÚ Çǵå¹éÀ» À¯µµÇϰí, ÀüÀÚ ÀÇ·á ±â·Ï(EHR) ¹× µðÁöÅÐ Ä¡·á Ç÷§Æû°ú µ¿±âÈ­ÇÕ´Ï´Ù. ÀÌ ¾ÛÀÇ AI ±â¹Ý ¿£ÁøÀº °³ÀÎÈ­µÈ ¾Ë¸², ¿¹Ãø ºÐ¼®, Àå±âÀûÀÎ º¹¾à ¼øÀÀµµ¸¦ Çâ»ó½ÃŰ´Â °ÔÀÓÈ­ ¿ä¼Ò¸¦ Á¦°øÇÕ´Ï´Ù. ²É°¡·ç ºñ»ê·®, °ø±âÁú, ½Àµµ µî ȯ°æÀû ¿äÀΰú ÈíÀԱ⠻ç¿ë »óȲÀ» ¿¬°ü½Ã۱â À§ÇØ Áö¸®Àû À§Ä¡ ÃßÀû ±â´ÉÀ» ³»ÀåÇÑ ÀåÄ¡µµ ÀÖ½À´Ï´Ù.

Ŭ¶ó¿ìµå ÅëÇÕ°ú »óÈ£¿î¿ë¼ºÀÌ Áß¿äÇÑ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½º¸¶Æ® ÈíÀÔ±â´Â ¿þ¾î·¯ºí »ê¼ÒÆ÷È­µµÃøÁ¤±â, »ê¼ÒÆ÷È­µµÃøÁ¤±â, ½º¸¶Æ® ÇÇÅ© À¯·®°è µî ±¤¹üÀ§ÇÑ È£Èí±â ¸ð´ÏÅ͸µ ½Ã½ºÅÛ°ú ÅëÇÕÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ ¸ÖƼ µð¹ÙÀ̽º ȯ°æÀº ÀÓ»óÀÇ¿¡°Ô ȯÀÚÀÇ °Ç°­ »óŸ¦ 360µµ µÑ·¯º¼ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¶ÇÇÑ, HIPAA ¹× GDPRÀ» ÁؼöÇÏ´Â µ¥ÀÌÅÍ ¾Ïȣȭ, ¿ªÇÒ ±â¹Ý ¾×¼¼½º, ¾ÈÀüÇÑ Å¬¶ó¿ìµå ½ºÅ丮Áö¸¦ ÅëÇØ ±ÔÁ¦ ½ÃÀå¿¡¼­ÀÇ µ¥ÀÌÅÍ º¸¾ÈÀ» º¸ÀåÇÕ´Ï´Ù. Á¦Á¶»çµéÀº ¶ÇÇÑ ½Ç½Ã°£ Áø·á Á¶Á¤ ¹× ¿ø°Ý Áø´ÜÀ» °¡´ÉÇÏ°Ô Çϱâ À§ÇØ À½¼º ºñ¼­ ÅëÇÕ ¹× ¿ø°ÝÀÇ·á ¿¬°áÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù.

½º¸¶Æ® ÈíÀԱ⸦ »ç¿ëÇϴ ȯÀÚÃþ°ú ÄÉ¾î »ýŰè´Â?

½º¸¶Æ® ÈíÀÔ±â´Â Áߵ¿¡¼­ ÁßÁõÀÇ Ãµ½Ä, COPD, ¾Ë·¹¸£±â¼º ±â°üÁö¿° ȯÀÚ, ƯÈ÷ Àå±âÀûÀÎ Á¶Àý±â Ä¡·á³ª ´Ù¾àÁ¦ ¿ä¹ýÀ» »ç¿ëÇϴ ȯÀÚµé »çÀÌ¿¡¼­ Å« È£ÀÀÀ» ¾ò°í ÀÖ½À´Ï´Ù. ¼Ò¾Æ ȯÀÚ¿Í ³ëÀÎÀº ºÎÀûÀýÇÑ ½Ã¼ú°ú ¼øÀÀµµ ÀúÇÏÀÇ À§ÇèÀÌ ³ô±â ¶§¹®¿¡ Áß¿äÇÑ Å¸°Ù ±×·ìÀÔ´Ï´Ù. °£º´ÀÎ, ¼Ò¾Æ°ú ÀÇ»ç, È£Èí±â Àü¹®ÀÇ, È£Èí Ä¡·á»çµéÀº ü°èÀûÀÎ Áúº´ °ü¸® °èȹÀÇ ÀÏȯÀ¸·Î ÀÌ·¯ÇÑ ±â±â¸¦ ±ÇÀåÇϰí ÀÖ½À´Ï´Ù. ¼Ò¾Æ ÀÇ·áÀÇ °æ¿ì, º¸È£ÀÚ°¡ Á¢±ÙÇÒ ¼ö ÀÖ´Â ´ë½Ãº¸µå¿Í ¿ø°Ý ¾Ë¸²À» ÅëÇØ Á¶±â °³ÀÔ°ú ÀÀ±Þ½Ç ¹æ¹®À» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

ÇコÄÉ¾î ½Ã½ºÅÛ, º¸Çè»ç, Á¦¾àȸ»çµµ ½º¸¶Æ® ÈíÀԱ⠽ÃÀå¿¡ Âü¿©Çϰí ÀÖ½À´Ï´Ù. ÁöºÒÀÚ´Â ÀÌ·¯ÇÑ ÀåÄ¡¸¦ °¡Ä¡ ±â¹Ý Ä¡·á ¸ðµ¨¿¡ ¹­¾î ¾à¹° ¼øÀÀµµ ¹× ȯÀÚ º¸°í °á°ú°¡ »óȯÀ²¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °¡Ä¡ ±â¹Ý Ä¡·á ¸ðµ¨¿¡ Àû¿ëÇϰí ÀÖ½À´Ï´Ù. º´¿ø°ú ACO(Accountable Care Organization)´Â ȯÀÚÀÇ È¸º¹À» ¸ð´ÏÅ͸µÇϰí ÀçÀÔ¿øÀ» ¹æÁöÇϱâ À§ÇØ Åð¿ø ÈÄ Å°Æ®¿¡ ½º¸¶Æ® ÈíÀԱ⸦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, Á¦¾à»çµéÀº ÀÚ»ç ºê·£µå ÈíÀÔÁ¦¿¡ ½º¸¶Æ® ¾Öµå¿Â ¸ðµâÀ» °øµ¿ °³¹ßÇÏ¿© µ¥ÀÌÅÍÀÇ ¿¬¼Ó¼º°ú Ä¡·áÀÇ °¡½Ã¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

¹Ì±¹, ¿µ±¹, EU ±¹°¡¿¡¼­´Â ÇコÄɾîÀÇ µðÁöÅÐÈ­ ¹× »óȯ ¸ðµ¨ÀÌ ¿ø°Ý ¸ð´ÏÅ͸µÀ» Áö¿øÇϰí ÀÖÀ¸¸ç, ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº µµ½Ã °øÇØ¿Í °ü·ÃµÈ È£Èí±âÁúȯ, ½º¸¶Æ®Æù º¸±Þ, ¿ø°ÝÀÇ·á ÀÎÇÁ¶ó Áõ°¡¿¡ ÈûÀÔ¾î °í¼ºÀå Áö¿ªÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿Àº ±¹Á¦º¸°Ç±â±¸¿Í ¹Î°ü ÆÄÆ®³Ê½ÊÀÇ Áö¿øÀ» ¹Þ¾Æ ½Ã¹üÀûÀ¸·Î Àü°³Çϰí ÀÖ½À´Ï´Ù.

¼¼°è ½º¸¶Æ® ÈíÀԱ⠽ÃÀåÀ» ¹ßÀü½ÃŰ´Â ÈûÀº ¹«¾ùÀϱî?

¼¼°è ½º¸¶Æ® ÈíÀԱ⠽ÃÀåÀÇ ¼ºÀåÀº È£Èí±âÁúȯÀÇ ¼¼°è ºÎ´ã Áõ°¡, °¡Ä¡ ±â¹Ý Ä¡·á·ÎÀÇ Àüȯ, µðÁöÅÐ Ä¡·áÁ¦ÀÇ ÅëÇÕ Áõ°¡, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ Ã߻꿡 µû¸£¸é, Àü ¼¼°è 2¾ï 6,200¸¸ ¸í ÀÌ»óÀÌ Ãµ½Ä, 2¾ï ¸í ÀÌ»óÀÌ COPD¸¦ ¾Î°í ÀÖ¾î Àå±âÀûÀÎ °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ Å« ¼ö¿ä°¡ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù. ½º¸¶Æ® ÈíÀÔ±â´Â Ä¡·á ¼øÀÀµµ¸¦ ÃøÁ¤ °¡´ÉÇÑ °á°ú·Î ÀüȯÇÏ¿© ¾ÇÈ­, ÀÀ±Þ½Ç ¹æ¹® ¹× ÇÕº´Áõ°ú °ü·ÃµÈ ÀÇ·á ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù.

ÁöºÒÀÚ ÁÖµµÀÇ µðÁöÅÐ Çコ ÀÌ´Ï¼ÅÆ¼ºê¿Í Á¤ºÎ ȯ±Þ ÇÁ·Î±×·¥ÀÌ Ã˸ÅÁ¦ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â CMS¿Í ¹Î°£ º¸Çè»ç°¡ ½º¸¶Æ® ÈíÀԱ⠵¥ÀÌÅ͸¦ ÀÓ»ó ¿öÅ©Ç÷ο쿡 ÅëÇÕÇÏ´Â RPM(¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ) ¼­ºñ½º¿¡ ÀÚ±ÝÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. FDA¿Í EMAµµ ¿©·¯ ½º¸¶Æ® ÈíÀԱ⠽ýºÅÛÀ» ½ÂÀÎÇÏ¿© ÀÇ»çÀÇ ½Å·Ú¿Í ȯÀÚÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ½Ã½ºÅÛÀÌ ¹ÝÀÀÀû Ä¡·á¿¡¼­ ¿¹ÃøÀû Ä¡·á·Î ÀüȯÇÏ´Â °¡¿îµ¥, ½º¸¶Æ® ÈíÀÔ±â´Â ½Ç½Ã°£ ÀÓ»ó °³ÀÔ µµ±¸·Î¼­ Àü·«Àû °ü·Ã¼ºÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

Àü·«Àû Á¦ÈÞ°¡ »ýŰèÀÇ ¼º¼÷À» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ±â±â Á¦Á¶¾÷ü´Â Á¦¾àȸ»ç, EHR Ç÷§Æû, µðÁöÅÐ Ä¡·áÁ¦ ±â¾÷°ú Á¦ÈÞÇÏ¿© ¿£µå Åõ ¿£µå È£Èí±â ÄÉ¾î ¼Ö·ç¼ÇÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á±â¼ú º¥Ã³ ijÇÇÅÐ ÆÝµåÀÇ ÅõÀÚµµ ´õ ³ôÀº Á¤È®µµ, °­È­µÈ ¹èÅ͸® ¼ö¸í, AI¸¦ Ȱ¿ëÇÑ ºÐ¼®À» °®Ãá Â÷¼¼´ë µð¹ÙÀ̽ºÀÇ ¿¬±¸°³¹ß¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù. ´ë±â ¿À¿°ÀÇ Áõ°¡, COVID ÀÌÈÄ È£Èí±â Ãë¾à¼º Áõ°¡, µðÁöÅÐ °Ç°­ ÅëÇÕÀÇ È®´ë·Î ÀÎÇØ ½º¸¶Æ® ÈíÀÔ±â´Â Àü ¼¼°è ¸¸¼º È£Èí±âÁúȯ °ü¸®ÀÇ Ç¥ÁØ Ä¡·á¹ýÀÌ µÉ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(ÈíÀÔ±â, ³×ºí¶óÀÌÀú), ¿ëµµ(õ½Ä, COPD)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Smart Inhalers Market to Reach US$192.2 Million by 2030

The global market for Smart Inhalers estimated at US$99.0 Million in the year 2024, is expected to reach US$192.2 Million by 2030, growing at a CAGR of 11.7% over the analysis period 2024-2030. Inhalers, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$110.8 Million by the end of the analysis period. Growth in the Nebulizers segment is estimated at 14.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$26.0 Million While China is Forecast to Grow at 11.1% CAGR

The Smart Inhalers market in the U.S. is estimated at US$26.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$30.1 Million by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.5% and 10.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.7% CAGR.

Global Smart Inhalers Market - Key Trends & Drivers Summarized

How Are Smart Inhalers Addressing Long-Standing Challenges in Respiratory Therapy?

Smart inhalers are transforming the management of chronic respiratory conditions like asthma and Chronic Obstructive Pulmonary Disease (COPD) by combining traditional inhalation mechanisms with digital connectivity, sensors, and data analytics. These devices capture real-time usage data, measure inhalation patterns, monitor adherence, and transmit information to patients and healthcare providers through Bluetooth-enabled mobile apps. By bridging the data gap between patient behavior and clinical outcomes, smart inhalers are empowering proactive disease management and personalized treatment optimization.

A key limitation in traditional inhaler therapies has been patient non-adherence and incorrect inhalation technique-factors that significantly reduce treatment efficacy. Smart inhalers address these issues by tracking dose accuracy, frequency, and timing, and by providing audio-visual reminders or coaching feedback to correct usage behavior. The resulting data helps clinicians assess symptom control, fine-tune medication regimens, and reduce avoidable hospitalizations. For patients, particularly children, the elderly, and those with low health literacy, smart inhalers offer real-time support and accountability that is critical for disease control.

What Technologies and Features Are Driving Innovation in Smart Inhalation Devices?

Smart inhalers leverage a suite of integrated technologies that enable real-time monitoring, data capture, and decision support. Embedded flow sensors and accelerometers detect inhalation strength, duration, and frequency, while microcontrollers record actuation events. Bluetooth Low Energy (BLE) modules transmit this data to companion mobile applications or cloud dashboards, where it can be analyzed and shared with healthcare professionals. Some models use acoustic sensors to assess breathing sounds and differentiate between coughing, wheezing, or proper inhalation.

Mobile applications play a central role in user engagement. They visualize trends, send medication reminders, prompt user feedback, and sync with electronic health records (EHRs) or digital therapeutics platforms. AI-based engines within these apps provide personalized alerts, predictive analytics, and even gamification elements to improve long-term adherence. Some devices are incorporating geolocation features to correlate inhaler usage with environmental triggers such as pollen count, air quality, or humidity levels-especially useful in managing condition flare-ups in asthma patients.

Cloud integration and interoperability are becoming key enablers. Smart inhalers are being designed to integrate with broader respiratory monitoring systems that include wearable spirometers, oximeters, and smart peak flow meters. This multi-device environment offers clinicians a 360-degree view of patient health. Additionally, HIPAA- and GDPR-compliant data encryption, role-based access, and secure cloud storage are ensuring data security in regulated markets. Manufacturers are also exploring voice-assistant integration and telehealth connectivity to allow real-time care coordination and remote diagnostics.

Which Patient Demographics and Care Ecosystems Are Adopting Smart Inhalers?

Smart inhalers are gaining traction among patients with moderate to severe asthma, COPD, and allergic bronchitis, especially those on long-term controller therapy or polypharmacy regimens. Pediatric patients and the elderly are key target groups due to their higher risk of improper technique and lower adherence. Caregivers, pediatricians, pulmonologists, and respiratory therapists are increasingly recommending these devices as part of structured disease management plans. In pediatric care, parent-accessible dashboards and remote alerts enable early intervention and reduced emergency visits.

Healthcare systems, insurance providers, and pharmaceutical companies are also engaging with the smart inhaler market. Payers are bundling these devices into value-based care models, where medication adherence and patient-reported outcomes impact reimbursement rates. Hospitals and ACOs (Accountable Care Organizations) are deploying smart inhalers in post-discharge kits to monitor patient recovery and prevent readmissions. Meanwhile, pharma companies are co-developing smart add-on modules for their branded inhaler drugs to ensure data continuity and improved treatment visibility.

The market is expanding in the U.S., U.K., and EU countries where healthcare digitization and reimbursement models support remote monitoring. Asia-Pacific is emerging as a high-growth region, driven by urban pollution-related respiratory disorders, smartphone adoption, and increased telehealth infrastructure. Latin America and the Middle East are witnessing pilot deployments supported by international health organizations and public-private partnerships.

What Forces Are Propelling the Global Smart Inhalers Market Forward?

The growth in the global smart inhalers market is driven by several factors, including the rising global burden of respiratory diseases, the shift toward value-based care, increasing integration of digital therapeutics, and growing demand for remote patient monitoring. According to WHO estimates, over 262 million people suffer from asthma and more than 200 million from COPD globally-creating significant demand for long-term management solutions. Smart inhalers offer a way to translate therapy adherence into measurable outcomes and reduce healthcare costs associated with exacerbations, ER visits, and complications.

Payer-driven digital health initiatives and government reimbursement programs are playing a catalytic role. In the U.S., CMS and private insurers are funding RPM (Remote Patient Monitoring) services that integrate smart inhaler data into clinical workflows. The FDA and EMA have also approved multiple smart inhaler systems, boosting physician confidence and patient adoption. As healthcare systems transition from reactive treatment to predictive care, smart inhalers are gaining strategic relevance as tools for real-time clinical intervention.

Strategic collaborations are accelerating ecosystem maturity. Device manufacturers are partnering with pharma companies, EHR platforms, and digital therapeutics firms to deliver end-to-end respiratory care solutions. Investments from medtech venture capital funds are also boosting R&D for next-gen devices with higher precision, enhanced battery life, and AI-powered analytics. With rising air pollution, increased respiratory vulnerability post-COVID, and broader digital health integration, smart inhalers are poised to become the standard of care in chronic respiratory disease management worldwide.

SCOPE OF STUDY:

The report analyzes the Smart Inhalers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Inhalers, Nebulizers); Application (Asthma Application, COPD Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â